Clostridium Difficile infections Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

Clostridium Difficile infections Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

Clostridium Difficile infections Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Clostridium Difficile infections Pipeline Analysis report covers drugs of 37 companies currently in different phases of development. Clostridium Difficile infections are caused by a bacterium, Clostridium difficile which causes diarrhoea and serious intestinal conditions known as colitis. Older people using antibiotics have a higher chance of getting the infections. Symptoms include watery diarrhoea, fever, loss of appetite, nausea and abdominal pain or cramps.

The report provides Clostridium Difficile infections treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Novartis AG, Sanofi, Pfizer Inc., Crestone Inc., PROKARIUM and Nestlé Health Science among others.

Scope:

  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Absynth Biologics
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. XBiotech
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Vitality Biopharma
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Valneva SE
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Valevia
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Astellas Pharma Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Seres Therapeutics
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Summit Therapeutics plc
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Otsuka Holdings Co., Ltd.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Immuron
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Actelion Pharmaceuticals Ltd 6.12.1. Introduction
6.12.1. Financials
6.12.2. Products and Services
6.12.3. SWOT
6.13. Novartis AG
6.13.1. Introduction
6.13.1. Financials
6.13.2. Products and Services
6.13.3. SWOT
6.14. Sanofi
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Synthetic Biologics, Inc.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. ImmuneBiotech AB
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Finch Therapeutics Group
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. PROKARIUM
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. C3J Therapeutics
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. Crestone Inc.
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services

  • SKU:
  • Publishing Date: 2018-06-14
  • Product Code: 1
  • Availability: In Stock
  • $2,400.00
  • Ex Tax: $2,400.00

Available Options